PET tracer developer Piramal Imaging said that four studies evaluating the company's F-18 florbetaben PET amyloid imaging agent will be presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting.
Andrew Stephens, vice president of clinical research and development, will also present an update on florbetaben PET imaging in clinical trials as part of SNMMI's Emerging Technologies Session on Neurodegenerative Imaging. The presentation will highlight the clinical experience with florbetaben based on more than 900 applications at imaging centers in the U.S., Europe, Japan, and Australia.
Florbetaben is currently being reviewed by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for use in the visual detection of beta amyloid in the brains of adults with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline, according to Piramal.
